Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumour and has poor prognosis. Currently, systematic chemotherapy is the only approach to prolong survival. Thus the development of new treatment regimens is urgently needed to improve the therapeutic efficacy. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Li, Zhu, Yuanrun, Shao, Jinjin, Chen, Min, Yan, Hao, Li, Guanqun, Zhu, Yi, Xu, Zhifei, Yang, Bo, Luo, Peihua, He, Qiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396112/
https://www.ncbi.nlm.nih.gov/pubmed/28267710
http://dx.doi.org/10.1038/bjc.2017.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396112/
https://www.ncbi.nlm.nih.gov/pubmed/28267710
http://dx.doi.org/10.1038/bjc.2017.55

Ejemplares similares